Clinical implications of CD47 and programmed death-ligand 1 expression in predicting the therapeutic response of immune checkpoints in advanced nonsmall-cell lung cancer
Shengchao Miao, Yaping Guan, Huanan Chen, Yuxia Cheng, Hongtao Liu, Yan Guo, Xin YeABSTRACT
Purpose:
This study aimed to evaluate CD47 expression in nonsmall-cell lung cancer (NSCLC) and explore the predictive value of combined CD47 and programmed death-ligand 1 (PD-L1) status for immunotherapy outcomes.
Materials and Methods:
Specimens from 59 patients with advanced NSCLC who were diagnosed or surgically resected and subsequently received immune checkpoint inhibitors (ICIs) were retrospectively collected for CD47 and PD-L1 detection by immunohistochemistry (IHC) and multiplex fluorescent IHC. A receiver operating characteristic (ROC) curve was constructed to determine the optimal CD47 cutoff value, and patients were categorized into four groups based on the IHC results: low CD47/negative–low PD-L1, high CD47/negative–low PD-L1, low CD47/high PD-L1, and high CD47/high PD-L1. In addition, the correlation between marker expression and clinical outcomes was analyzed.
Results:
CD47 positivity was observed in 53 cases, 29 (54.7%) of which showed the coexpression of PD-L1/CD47. ROC analysis defined the threshold for high CD47 expression as >38.9% stained tumor cells. Multivariate analysis identified CD47 and PD-L1 as independent prognostic factors for immunotherapy efficacy (CD47: PFS
Conclusion:
The combined assessment of CD47 and PD-L1 performed excellently in predicting responses to ICIs in advanced NSCLC, and this approach may serve as a potential predictive biomarker for immunotherapy.